Abstract:Guided by molecular docking, a commonly used open-chain linker was cyclized into a five-membered pyrrolidine to lock the overall conformation of the propeller-shaped molecule. Different substituents were introduced into the pyrrolidine moiety to block oxidative metabolism. Surprisingly, it was found that a small methyl substituent could be used to alleviate the oxidative metabolism of pyrrolidine while maintaining or enhancing potency, which could be described as a "magic methyl". Further optimization around the "3rd blade" of the propeller led to identification of a series of potent and selective PI3Kδ inhibitors. Among them, compound 50 afforded an optimum balance of PK profiles and potency. Oral administration of 50 attenuated the arthritis severity in a dose-dependent manner in a collagen-induced arthritis model without obvious toxicity. Furthermore, 50 demonstrated excellent pharmacokinetic properties with high bioavailability, suggesting that 50 might be an acceptable candidate for treatment of inflammatory diseases.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00004?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00004</a>.Binding affinities of 50 with 164 kinases (Table S1); predicted results of compound 43 from the CYP3A4, CYP2D6, and CYP2C9 models, respectively, in SMARTCyp (Tables S2–S4); effects of compound 50 and idelalisib on normal cell viability (Table S5); binding free energy (ΔGbindcal) for idelalisib/PI3Kδ complexes (Table S6); binding free energy (ΔGbindcal) for compound 50/PI3Kδ complexes (Table S7); cocrystal structure of 1 in PI3Kδ (Figure S1); docking model of compound 29 in PI3Kδ (Figure S2); pre-experiments of selected compounds and dexamethasone in collagen-induced arthritis models (Figure S3); snapshots of the idelalisib/PI3Kδ complex along the dynamic simulation time for 100th, 200th, 300th, 400th, and 500th ns (Figure S4); snapshots of the compound 50/PI3Kδ complex along the dynamic simulation time at 100th, 200th, 300th, 400th, and 500th ns (Figure S5); therapeutic efficacy of 50 in mice-established collagen-induced arthritis (Figure S6); HPLC spectra of compound 50 (Figure S6); 1H NMR spectra of compounds 26, 30, 45, 46, 47, 49, and 50 (Figures S8, S9, S10, S11, S12, S13, and S14, respectively); and biological assay methods: (1) kinase profile assay and IC50 test; (2) class I PI3K isoform-selective cellular assays (SKOV-3, 786-O, RAW 264.7, and RAJI cell lines); (3) basophil activation assay in HWB; (4) B cell activation assay in HWB; (5) primary human T-cell proliferation assays; (6) microsome stability assay; (7) pharmacokinetic study; (8) collagen-induced arthritis (CIA) model and treatment; and (9) histological examination (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00004/suppl_file/jm1c00004_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00004/suppl_file/jm1c00004_si_003.csv">CSV</a>)PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0">4XE0</a> was used for docking in PI3Kδ of compounds 10, 29, 43, and 50 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00004/suppl_file/jm1c00004_si_002.zip">ZIP</a>)This article has not yet been cited by other publications.

Discovery of ( S )-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1 H -pyrazolo[3,4- d ]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3 H )-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease

Discovery of (S)-2-(1-(4-amino-3-(3-fluoro-4-methoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3h)-one (Ihmt-Pi3kδ-372) As a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease

Advances in the Discovery of Novel Inhaled PI3K Inhibitors for the Treatment of Asthma

Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory Diseases

Discovery of Pyrazolo[1,5- a ]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor

Discovery of (S)-2-amino-n-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) As a Potent and Selective Phosphoinositide 3-Kinase Delta (pi3kδ) Inhibitor.

Structurally Novel PI3Kδ/γ Dual Inhibitors Characterized by a Seven-Membered Spirocyclic Spacer: the SARs Investigation and PK Evaluation.

Discovery of a Series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides As PI3K/mTOR Dual Inhibitors

Discovery of Highly Selective and Orally Bioavailable PI3Kδ Inhibitors with Anti-Inflammatory Activity for Treatment of Acute Lung Injury.

Discovery of Pyrazolo[1,5- a ]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.

Discovery of CHF-6523, an Inhaled Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease

Discovery of Novel Pyrido[3,2-D]pyrimidine Derivatives As Selective and Potent PI3Kδ Inhibitors.

Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis.

Discovery of Novel Quinazoline Derivatives As Potent PI3Kδ Inhibitors with High Selectivity.

Discovery of a Potent and Selective FLT3 Inhibitor ( Z )- N -(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1 H -pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia

Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor.